Zymeworks (NYSE:ZYME) is a clinical-stage biopharmaceutical company headquartered in Vancouver, British Columbia, with a focus on the discovery, development and commercialization of multifunctional biotherapeutics. Founded in 2003, the company applies proprietary protein engineering platforms to create novel antibody and protein-based therapies targeting oncology and other serious diseases. Zymeworks is publicly traded on the New York Stock Exchange under the symbol ZYME.
The company’s core technology platforms include Azymetric®, which enables the design of bispecific antibodies capable of engaging two distinct targets simultaneously, and the EFECT™ platform for fine-tuning antibody-drug conjugate properties. Zymeworks’ leading clinical-stage candidates include zanidatamab (ZW25), a bispecific antibody targeting two unique sites on the HER2 receptor, currently under investigation in multiple solid tumor indications. In addition to its in-house pipeline, Zymeworks has established collaborations with global pharmaceutical partners to co-develop and license select candidates, leveraging external expertise and resources to accelerate clinical advancement.
With research and development facilities in Canada and the United States, Zymeworks supports a broad clinical program that spans Phase 1 through Phase 3 studies. The company’s manufacturing capabilities are designed to support both early-stage research batches and larger-scale production for pivotal trials. Zymeworks maintains a commitment to robust translational science and uses biomarker-driven strategies to inform patient selection and enhance the probability of clinical success.
Led by a management team with extensive experience in biologics development, regulatory affairs and commercial operations, Zymeworks continues to strengthen its leadership bench through strategic appointments in clinical research and corporate development. As the company advances its pipeline, it aims to address high-unmet-need indications in oncology and beyond, positioning itself as a versatile player in the evolving field of multispecific antibody therapeutics.
